Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Common Equity (2016 - 2026)

Viridian Therapeutics, Inc.\DE has reported Common Equity over the past 14 years, most recently at $636.0 million for Q1 2026.

  • For Q1 2026, Common Equity rose 5.22% year-over-year to $636.0 million; the TTM value through Mar 2026 reached $636.0 million, up 5.22%, while the annual FY2025 figure was $722.2 million, 7.52% up from the prior year.
  • Common Equity for Q1 2026 was $636.0 million at Viridian Therapeutics, Inc.\DE, down from $722.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $722.2 million in Q4 2025 and troughed at $141.9 million in Q2 2022.
  • A 5-year average of $469.2 million and a median of $503.0 million in 2025 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: tumbled 30.67% in 2023 and later surged 149.49% in 2024.
  • Year by year, Common Equity stood at $395.1 million in 2022, then increased by 11.89% to $442.0 million in 2023, then soared by 51.95% to $671.6 million in 2024, then grew by 7.52% to $722.2 million in 2025, then dropped by 11.93% to $636.0 million in 2026.
  • Business Quant data shows Common Equity for VRDN at $636.0 million in Q1 2026, $722.2 million in Q4 2025, and $503.0 million in Q3 2025.